The U.K.’s push for COVID-19 master protocols pays off again with definitive data on lopinavir-ritonavir

The U.K.’s RECOVERY trial and broader strategy to encourage master protocol participation are proving their value again, this time with data showing that the lopinavir-ritonavir antiviral cocktail has no clinical benefit in hospitalized patients not on a ventilator.

The readout is the third this month for the randomized, controlled adaptive trial, and lends additional support to the master protocol model as the fastest and most efficient way to generate statistically powered clinical data during the pandemic and beyond (see “Master Protocols Emerge”.)...